Cargando…
502P Association of immunotherapy and immunosuppression with severe COVID-19 disease in patients with cancer
Autores principales: | Bakouny, Z., Grover, P., Labaki, C., Awosika, J., Gulati, S., Hsu, C-Y., Bilen, M.A., Eton, O., Fecher, L., Hwang, C., Khan, H., McKay, R.R., Ruiz, E., Weissmann, L., Thompson, M.A., Shah, D., Warner, J., Shyr, Y., Choueiri, T.K., Wise-Draper, T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472565/ http://dx.doi.org/10.1016/j.annonc.2022.07.630 |
Ejemplares similares
-
COVID-19 vaccination and breakthrough infections in patients with cancer
por: Schmidt, A.L., et al.
Publicado: (2022) -
Recovery of cancer screening tests and possible associated disparities after the first peak of the COVID-19 pandemic
por: Labaki, Chris, et al.
Publicado: (2021) -
First-Line Treatments for Metastatic Clear Cell Renal Cell Carcinoma: An Ever-Enlarging Landscape
por: Gulati, Shuchi, et al.
Publicado: (2022) -
LBA71 Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis
por: Wise-Draper, T.M., et al.
Publicado: (2020) -
501P A prognostic model of all-cause mortality at 30 days in patients with cancer and COVID-19
por: Halabi, S., et al.
Publicado: (2022)